Immuneering Corp is a US-based pharmaceutical company with a ESG score of 24.1, indicating medium risk. Specializing in the use of computational biology, Immuneering is dedicated to enhancing patient outcomes in oncologic and neurologic diseases. Their innovative Disease Cancelling Technology platform drives drug discovery efforts, while also offering computational biology services to other pharmaceutical and biotech firms.